Prof. Valentín Huerva

Director Department of Ophthalmology

Universitary Hospital Arnau de Vilanova, Lleida, Spain

University of Lleida, Spain

Email: [email protected]

Qualifications

1992  Especialist in Ophthalmology, Universitary Clinic Hospital of Zaragoza

1992  Formation stays in the Ophthalmology Departments, Universitary Hospital of Essen

1987  Degree in Medicine, Faculty of Medicine of Zaragoza

Publications (Selected)

1. Cid-Bertomeu P, Vilaltella M, Martínez M, Mir M, Huerva V. Topical Insulin for Ocular Surface Disease. J Ocul Pharmacol Ther. 2024 May;40(4):204-214. doi:10.1089/jop.2024.0016. Epub 2024 Mar 22. PMID: 38527183.
2. Cid-Bertomeu P, Vilaltella M, Huerva V. Undesirable High Astigmatism after Penetrating Keratoplasty in Pseudophakia Corrected with an Add-On Toric Intraocular Lens. Case Rep Ophthalmol. 2023 Jul 10;14(1):307-313. doi: 10.1159/000530281. PMID: 37485245; PMCID: PMC10359674.
3. Vilaltella M, Cid-Bertomeu P, Huerva V. Accuracy of 10 IOL power calculation formulas in 100 short eyes (≤ 22 mm). Int Ophthalmol. 2023 Aug;43(8):2613-2622.doi: 10.1007/s10792-023-02660-y. Epub 2023 Mar 27. PMID: 36971929.
4. Huerva V, Vilardell F, Cid-Bertomeu P. Cryotherapy after Topical Interferon Alpha 2b to Treat Conjunctival Primary Acquired Melanosis. Case Rep Ophthalmol.2023 Mar 22;14(1):111-114. doi: 10.1159/000529667. PMID: 36968810; PMCID:PMC10035544.
5. Huerva V, Cid-Bertomeu P, Espinet R, Canto LM. Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma. Ocul Oncol Pathol. 2022 Jun;8(2):88-92. doi: 10.1159/000522195. Epub 2022 Jan 27. PMID: 35959160; PMCID:PMC9218643.
6. Cid-Bertomeu P, Huerva V. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma. Surv Ophthalmol. 2022 Sep-Oct;67(5):1391-1404. doi: 10.1016/j.survophthal.2022.03.003. Epub 2022 Mar 9.PMID: 35278438.
7. Vilaltella M, Huerva V. The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size. Arq Bras Oftalmol. 2021 Aug 18;85(2):109-114. doi:10.5935/0004-2749.20220018. PMID: 34431893.
8. Huerva V, Vilaltella M. Ocular surface squamous neoplasia resistant to topical interferon alpha 2b in a patient with follicular lymphoma. Int J Ophthalmol. 2021 Jul 18;14(7):1122-1124. doi: 10.18240/ijo.2021.07.24. PMID:34282401; PMCID: PMC8243178.
9. Vilaltella M, Vilardell F, Cid-Bertomeu P, Huerva V. IgG₄-related orbital disease. Can J Ophthalmol. 2022 Jun;57(3):e78-e79. doi: 10.1016/j.jcjo.2021.05.016. Epub 2021 Jun 24. PMID: 34174214.
10. Pont C, Ascaso FJ, Grzybowski A, Huerva V. Corneal endothelial cell density during diabetes mellitus and ocular diabetes complications treatment. J Fr Ophtalmol. 2020 Oct;43(8):794-798. doi: 10.1016/j.jfo.2019.12.003. Epub 2020 Jun29. PMID: 32616318.
11. Huerva V, Ascaso FJ, Grzybowski A. Diabetic Ocular Surface and Anterior Segment Pathology. J Ophthalmol. 2019 Aug 14;2019:5951398. doi: 10.1155/2019/5951398. PMID: 31485345; PMCID: PMC6710789.
12. Huerva V. Re: Ip et al.: Primary acquired melanosis treated with combination interferon and retinoic acid (Ophthalmology. 2018;125:1994-1996). Ophthalmology.2019 Sep;126(9):e67. doi: 10.1016/j.ophtha.2019.03.025. PMID: 31443793.
13. Del Buey MA, Casas P, Caramello C, López N, de la Rica M, Subirón AB, Lanchares E, Huerva V, Grzybowski A, Ascaso FJ. An Update on Corneal Biomechanics and Architecture in Diabetes. J Ophthalmol. 2019 Jun2;2019:7645352. doi: 10.1155/2019/7645352. PMID: 31275634; PMCID: PMC6589322.
14. Grzybowski A, Kanclerz P, Huerva V, Ascaso FJ, Tuuminen R. Diabetes and Phacoemulsification Cataract Surgery: Difficulties, Risks and Potential Complications. J Clin Med. 2019 May 20;8(5):716. doi: 10.3390/jcm8050716. PMID:31137510; PMCID: PMC6572121.
15. Matas-Nadal C, Sòria X, García-de-la-Fuente MR, Huerva V, Ortega E, Vilardell F, Gatius S, Casanova JM, Martí RM. Immunocryosurgery as monotherapyfor lentigo maligna or combined with surgical excision for lentigo malignamelanoma. J Dermatol. 2018 May;45(5):564-570. doi: 10.1111/1346-8138.14248. Epub 2018 Feb 11. PMID: 29430695.
16. Huerva V, Castanera D. Upper eyelid ectropion repair. BMJ Case Rep. 2017 Sep19;2017:bcr2017221982. doi: 10.1136/bcr-2017-221982. PMID: 28928260; PMCID:PMC5747684.
17. Huerva V, Pont C, Castanera D. Opaque intraocular lens for correction of intractable diplopia and torticollis. BMJ Case Rep. 2017 Aug 3;2017:bcr2017221242. doi: 10.1136/bcr-2017-221242. PMID: 28775108; PMCID:PMC5624043.
18. Huerva V, Ascaso FJ, Caral I, Grzybowski A. Calculation of iris-claw IOL power for correction of late in-the-bag IOL complex dislocation. BMC Ophthalmol. 2017 Jul 11;17(1):122. doi: 10.1186/s12886-017-0516-1. PMID: 28693457; PMCID:PMC5504750.
19. Huerva V, Soldevila J. Alternaria alternata keratitis. Med Clin (Barc). 2017 Nov 22;149(10):466. English, Spanish. doi: 10.1016/j.medcli.2017.05.017. Epub2017 Jun 23. PMID: 28651877.
20. Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macularedema: update 2016. Clin Interv Aging. 2016 Sep 9;11:1221-1229. doi: 10.2147/CIA.S111761. PMID: 27672316; PMCID: PMC5025006.

Profile Details

WoS ResearcherID: A-6596-2010

https://orcid.org/0000-0003-3832-6981

https://www.scopus.com/authid/detail.uri?authorId=6602977364

https://www.researchgate.net/scientific-contributions/Valentin-Huerva-38291125